Targovax ASA announced the appointment of Dr. Torbjørn Furuseth as CFO, effective September 24, 2018. Dr. Erik Digman Wiklund, currently Targovax's CFO, will become Chief Business Officer, replacing Michael Bogenstaetter. Torbjørn joins from the clinical stage pharmaceutical company Lytix Biopharma, where he has served as CFO since February 2017, developing an integrated financing strategy and raising NOK 150 million in private rounds.

Erik was appointed CFO of Targovax in April 2017, and led the NOK 200 million private placement in June 2017.